HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cosmetics Stakeholders Race To Hitch Reform Provisions To FDA User-Fee Bills

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Council says consensus has nearly been reached between industry and consumer advocates on cosmetics reform provisions they hope to attach to FDA user-fee legislation. The groups must produce broadly supported, noncontroversial language by mid-March in order to have a shot at inclusion in the critical reauthorization bills, which typically pass well in advance of October deadlines.


Related Content

Cosmetics Provisions Unlikely To Catch Ride On FDA User-Fee Bill
Trump's Budget Blueprint: Cosmetics Opportunity Or Unhelpful Distraction?
PCPC Hatching Proposal For CIR Role In FDA Ingredient Review
Pending FDA User-Fee Legislation May Be ‘Big Shot’ For Cosmetics Reg Reform
Obamacare Repeal May Be Delaying User Fee Bill, Rep. DeGette Says
PCPC Statement On Cosmetics Reform Legislation Hints At Potential Compromises
House Cosmetics Bill Reintroduced; ICMAD Optimistic In New Political Climate





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts